Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 111-117

  Wang, Yanwen ^a,b   Jia, Xiaoming ^a   Ghanam, Khadija ^a,b   Beaurepaire, Cécile ^a   Zidichouski, Jeffrey ^a,b   Miller, Lisa ^b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

Berberine; Cholesterol absorption; Cholesterol synthesis; Hamster; LDL receptor; Plant stanols; Plasma lipids

Indexed keywords

BERBERINE; BILE ACID; CASEIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PHYTOSTEROL; STANOL DERIVATIVE; STARCH; STEROL 27 HYDROXYLASE; SUCROSE; TRACER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME CHEMISTRY; GENE EXPRESSION REGULATION; HAMSTER; HYPERCHOLESTEROLEMIA; ISOTOPE LABELING; LIPID BLOOD LEVEL; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING;

ABSORPTION; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BERBERINE; CHOLESTEROL; CRICETINAE; CYTOCHROME P-450 CYP27A1; DRUG SYNERGISM; GENE EXPRESSION; INTESTINE, SMALL; LIVER; MALE; MEMBRANE PROTEINS; ORGAN SIZE; RECEPTORS, LDL; SITOSTEROLS; TRIGLYCERIDES;

EID: 77049088672     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.050     Document Type: Article

References (47)

1. Zeng X.H., Zeng X.J., and Li Y.Y. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92 (2003) 173-176
2. Jagetia G.C., and Baliga M.S. Effect of Alstonia scholaris in enhancing the anticancer activity of berberine in the Ehrlich ascites carcinoma-bearing mice. J Med Food 7 (2004) 235-244
3. Kong W., Wei J., Abidi P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004) 1344-1351
4. Cicero A.F., Rovati L.C., and Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 57 (2007) 26-30
5. Abidi P., Chen W., Kraemer F.B., Li H., and Liu J. The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms. J Lipid Res 47 (2006) 2134-2147
6. Tang L.Q., Wei W., Chen L.M., and Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 108 (2006) 109-115
7. Vanstone C.A., Raeini-Sarjaz M., Parsons W.E., and Jones P.J. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr 76 (2002) 1272-1278
8. Wang Y., Jones P.J., Ausman L.M., and Lichtenstein A.H. Soy protein reduces triglyceride levels and triglyceride fatty acid fractional synthesis rate in hypercholesterolemic subjects. Atherosclerosis 173 (2004) 269-275
9. Jenkins D.J., Axelsen M., Kendall C.W., Augustin L.S., Vuksan V., and Smith U. Dietary fibre, lente carbohydrates and the insulin-resistant diseases. Br J Nutr 83 Suppl 1 (2000) S157-S163
10. Rutishauser J. The role of statins in clinical medicine - LDL - cholesterol lowering and beyond. Swiss Med Wkly 136 (2006) 41-49
11. Chang H.M., and But P.P.H. Pharmacology and applications of chinese materia medica (2000), World Scientific Publishing Co. Pte. Ltd., Farrer Road, Singapore p. 60
12. Oshiba S., Ueno H., Mihara H., and Okamoto S. Effect of berberine on bile secretion. Nihon Univ J Med 16 (1974) 69-79
13. Vartazaryan B.A., and Koltochnik E.E. Choleretic action of berberine Sb Nauchn Tr Vladivostoksk. Med Inst 2 (1964) 113-115
14. Mikes V., and Kovar J. Interaction of liposomes with homologous series of fluorescent berberine derivatives. New cationic probes for measuring membrane potential. Biochim Biophys Acta 640 (1981) 341-351
15. Megyesi M., and Biczok L. Berberine alkaloid as a sensitive fluorescent probe for bile salt aggregates. J Phys Chem B 111 (2007) 5635-5639
16. Miettinen T.A., Vuoristo M., Nissinen M., Jarvinen H.J., and Gylling H. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr 71 (2000) 1095-1102
17. Korpela R., Tuomilehto J., Hogstrom P., et al. Safety aspects and cholesterol-lowering efficacy of low fat dairy products containing plant sterols. Eur J Clin Nutr 60 (2006) 633-642
18. Jia X., Chen Y., Zidichouski J., Zhang J., Sun C., and Wang Y. Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats. Atherosclerosis (2008)
19. Suckling K.E., and Jackson B. Animal models of human lipid metabolism. Prog Lipid Res 32 (1993) 1-24
20. Reeves P.G., Nielsen F.H., and Fahey Jr. G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123 (1993) 1939-1951
21. Ntanios F.Y., MacDougall D.E., and Jones P.J. Gender effects of tall oil versus soybean phytosterols as cholesterol-lowering agents in hamsters. Can J Physiol Pharmacol 76 (1998) 780-787
22. Wang Y.W., Jones P.J., Pischel I., and Fairow C. Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 38 (2003) 165-170
23. Kris-Etherton P.M., and Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Am J Clin Nutr 65 (1997) 1590S-1596S
24. Ntanios F.Y., and Jones P.J. Dietary sitostanol reciprocally influences cholesterol absorption and biosynthesis in hamsters and rabbits. Atherosclerosis 143 (1999) 341-351
25. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
26. Jia X., Ebine N., Demonty I., et al. Hypocholesterolaemic effects of plant sterol analogues are independent of ABCG5 and ABCG8 transporter expressions in hamsters. Br J Nutr 98 (2007) 550-555
27. Field F.J., Born E., and Mathur S.N. Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-Like 1 protein gene expression. J Lipid Res 45 (2004) 2252-2259
28. Vlahcevic Z.R., Pandak W.M., Heuman D.M., and Hylemon P.B. Function and regulation of hydroxylases involved in the bile acid biosynthesis pathways. Semin Liver Dis 12 (1992) 403-419
29. Matsuzaki Y., Bouscarel B., Ikegami T., et al. Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver. Biochim Biophys Acta 1588 (2002) 139-148
30. Plosch T., Kosters A., Groen A.K., and Kuipers F. The ABC of hepatic and intestinal cholesterol transport. Handbook Exp Pharmacol (2005) 465-482
31. Plosch T., Kruit J.K., Bloks V.W., et al. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J Nutr 136 (2006) 2135-2140
32. Calpe-Berdiel L., Escola-Gil J.C., Ribas V., Navarro-Sastre A., Garces-Garces J., and Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis 181 (2005) 75-85
33. Kesaniemi Y.A., and Miettinen T.A. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 17 (1987) 391-395
34. Wang Y., Jones P.J., Woollett L.A., et al. Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl Res 148 (2006) 37-45
35. Matthan N.R., Pencina M., Larocque J.M., et al. Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease. J Lipid Res (2009)
36. Volger O.L., van der Boom H., de Wit E.C., et al. Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 21 (2001) 1046-1052
37. Repa J.J., Turley S.D., Quan G., and Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res 46 (2005) 779-789
38. Jeu L., and Cheng J.W. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 25 (2003) 2352-2387
39. van Heek M., Austin T.M., Farley C., Cook J.A., Tetzloff G.G., and Davis H.R. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 50 (2001) 1330-1335
40. Stein E. Results of phase 1/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 3 Suppl (2001) E11-E16
41. Telford D.E., Sutherland B.G., Edwards J.Y., Andrews J.D., Barrett P.H., and Huff M.W. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 48 (2007) 699-708
42. Ntanios F.Y., and Jones P.J. Effects of variable dietary sitostanol concentrations on plasma lipid profile and phytosterol metabolism in hamsters. Biochim Biophys Acta 1390 (1998) 237-244
43. Wang Y., Ebine N., Jia X., Jones P.J., Fairow C., and Jaeger R. Very long chain fatty acids (policosanols) and phytosterols affect plasma lipid levels and cholesterol biosynthesis in hamsters. Metabolism 54 (2005) 508-514
44. Egger M., Smith G.D., Pfluger D., Altpeter E., and Elwood P.C. Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis 143 (1999) 275-284
45. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 87 (2001) 2B-7B
46. Brusq J.M., Ancellin N., Grondin P., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47 (2006) 1281-1288
47. Lee Y.S., Kim W.S., Kim K.H., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55 (2006) 2256-2264